European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in
Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic
Factors for Treatment-Free Remission

J 2024

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

MAHON, Francois-Xavier, Markus PFIRRMANN, Stephanie DULUCQ, Andreas HOCHHAUS, Panayiotis PANAYIOTIDIS et. al.

Basic information

Original name

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Authors

MAHON, Francois-Xavier, Markus PFIRRMANN, Stephanie DULUCQ, Andreas HOCHHAUS, Panayiotis PANAYIOTIDIS, Antonio ALMEIDA, Jiří MAYER (203 Czech Republic, belonging to the institution), Henrik HJORTH-HANSEN, Jeroen J W M JANSSEN, Satu MUSTJOKI, Joaquin MARTINEZ-LOPEZ, Hanne VESTERGAARD, Hans EHRENCRONA, Katerina Machova POLAKOVA, Ulla OLSSON-STROEMBERG, Gert OSSENKOPPELE, Marc G BERGER, Gabriel ETIENNE, Jolanta DENGLER, Tim H BRUEMMENDORF, Andreas BURCHERT, Delphine REA, Philippe ROUSSELOT, Franck E NICOLINI, Wolf-Karsten HOFMANN, Johan RICHTER and Susanne SAUSSELE

Edition

Journal of clinical oncology, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2024, 0732-183X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 45.300 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1200/JCO.23.01647

UT WoS

001279720300007

Keywords in English

Chronic Myeloid Leukemia; EURO-SKI

Abstract

V originále

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The European Stop Kinase Inhibitors (EURO-SKI) study is the largest clinical trial for investigating the cessation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in stable deep molecular remission (DMR). Among 728 patients, 434 patients (61%; 95% CI, 57 to 64) remained in major molecular response (MMR) at 6 months and 309 patients of 678 (46%; 95% CI, 42 to 49) at 36 months. Duration of TKI treatment and DMR before TKI stop were confirmed as significant factors for the prediction of MMR loss at 6 months. In addition, the type of BCR::ABL1 transcript was identified as a prognostic factor. For late MMR losses after 6 months, TKI treatment duration, percentage of blasts in peripheral blood, and platelet count at diagnosis were significant factors in multivariate analysis. For the entire study period of 36 months, multiple logistic regression models confirmed duration of treatment, blasts, and transcript type as independent factors for MMR maintenance. In addition to the duration of treatment, transcript type as well as blasts in peripheral blood at diagnosis should be considered as important factors to predict treatment-free remission.

Citovat

MAHON, Francois-Xavier, Markus PFIRRMANN, Stephanie DULUCQ, Andreas HOCHHAUS, Panayiotis PANAYIOTIDIS, Antonio ALMEIDA, Jiří MAYER, Henrik HJORTH-HANSEN, Jeroen J W M JANSSEN, Satu MUSTJOKI, Joaquin MARTINEZ-LOPEZ, Hanne VESTERGAARD, Hans EHRENCRONA, Katerina Machova POLAKOVA, Ulla OLSSON-STROEMBERG, Gert OSSENKOPPELE, Marc G BERGER, Gabriel ETIENNE, Jolanta DENGLER, Tim H BRUEMMENDORF, Andreas BURCHERT, Delphine REA, Philippe ROUSSELOT, Franck E NICOLINI, Wolf-Karsten HOFMANN, Johan RICHTER and Susanne SAUSSELE. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. Journal of clinical oncology. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2024, vol. 42, No 16, p. 1-11. ISSN 0732-183X. Available from: https://dx.doi.org/10.1200/JCO.23.01647.

@article{2423182,
   author = {Mahon, FrancoisandXavier and Pfirrmann, Markus and Dulucq, Stephanie and Hochhaus, Andreas and Panayiotidis, Panayiotis and Almeida, Antonio and Mayer, Jiří and HjorthandHansen, Henrik and Janssen, Jeroen J W M and Mustjoki, Satu and MartinezandLopez, Joaquin and Vestergaard, Hanne and Ehrencrona, Hans and Polakova, Katerina Machova and OlssonandStroemberg, Ulla and Ossenkoppele, Gert and Berger, Marc G and Etienne, Gabriel and Dengler, Jolanta and Bruemmendorf, Tim H and Burchert, Andreas and Rea, Delphine and Rousselot, Philippe and Nicolini, Franck E and Hofmann, WolfandKarsten and Richter, Johan and Saussele, Susanne},
   article_location = {PHILADELPHIA},
   article_number = {16},
   doi = {http://dx.doi.org/10.1200/JCO.23.01647},
   keywords = {Chronic Myeloid Leukemia; EURO-SKI},
   language = {eng},
   issn = {0732-183X},
   journal = {Journal of clinical oncology},
   title = {European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission},
   url = {https://ascopubs.org/doi/10.1200/JCO.23.01647},
   volume = {42},
   year = {2024}
}

TY  - JOUR
ID  - 2423182
AU  - Mahon, Francois-Xavier - Pfirrmann, Markus - Dulucq, Stephanie - Hochhaus, Andreas - Panayiotidis, Panayiotis - Almeida, Antonio - Mayer, Jiří - Hjorth-Hansen, Henrik - Janssen, Jeroen J W M - Mustjoki, Satu - Martinez-Lopez, Joaquin - Vestergaard, Hanne - Ehrencrona, Hans - Polakova, Katerina Machova - Olsson-Stroemberg, Ulla - Ossenkoppele, Gert - Berger, Marc G - Etienne, Gabriel - Dengler, Jolanta - Bruemmendorf, Tim H - Burchert, Andreas - Rea, Delphine - Rousselot, Philippe - Nicolini, Franck E - Hofmann, Wolf-Karsten - Richter, Johan - Saussele, Susanne
PY  - 2024
TI  - European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission
JF  - Journal of clinical oncology
VL  - 42
IS  - 16
SP  - 1-11
EP  - 1-11
PB  - LIPPINCOTT WILLIAMS & WILKINS
SN  - 0732183X
KW  - Chronic Myeloid Leukemia
KW  - EURO-SKI
UR  - https://ascopubs.org/doi/10.1200/JCO.23.01647
N2  - Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The European Stop Kinase Inhibitors (EURO-SKI) study is the largest clinical trial for investigating the cessation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in stable deep molecular remission (DMR). Among 728 patients, 434 patients (61%; 95% CI, 57 to 64) remained in major molecular response (MMR) at 6 months and 309 patients of 678 (46%; 95% CI, 42 to 49) at 36 months. Duration of TKI treatment and DMR before TKI stop were confirmed as significant factors for the prediction of MMR loss at 6 months. In addition, the type of BCR::ABL1 transcript was identified as a prognostic factor. For late MMR losses after 6 months, TKI treatment duration, percentage of blasts in peripheral blood, and platelet count at diagnosis were significant factors in multivariate analysis. For the entire study period of 36 months, multiple logistic regression models confirmed duration of treatment, blasts, and transcript type as independent factors for MMR maintenance. In addition to the duration of treatment, transcript type as well as blasts in peripheral blood at diagnosis should be considered as important factors to predict treatment-free remission.
ER  -

MAHON, Francois-Xavier, Markus PFIRRMANN, Stephanie DULUCQ, Andreas HOCHHAUS, Panayiotis PANAYIOTIDIS, Antonio ALMEIDA, Jiří MAYER, Henrik HJORTH-HANSEN, Jeroen J W M JANSSEN, Satu MUSTJOKI, Joaquin MARTINEZ-LOPEZ, Hanne VESTERGAARD, Hans EHRENCRONA, Katerina Machova POLAKOVA, Ulla OLSSON-STROEMBERG, Gert OSSENKOPPELE, Marc G BERGER, Gabriel ETIENNE, Jolanta DENGLER, Tim H BRUEMMENDORF, Andreas BURCHERT, Delphine REA, Philippe ROUSSELOT, Franck E NICOLINI, Wolf-Karsten HOFMANN, Johan RICHTER and Susanne SAUSSELE. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. \textit{Journal of clinical oncology}. PHILADELPHIA: LIPPINCOTT WILLIAMS \&{} WILKINS, 2024, vol.~42, No~16, p.~1-11. ISSN~0732-183X. Available from: https://dx.doi.org/10.1200/JCO.23.01647.

Detailed Information on Publication Record